CHEST® Online Supplement

Airway Clearance Techniques in Bronchiectasis

Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry

Ashwin Basavaraj, MD; Radmila Choate, PhD, MPH; Doreen Addrizzo-Harris, MD; Timothy R. Aksamit, MD; Alan Barker, MD; Charles L. Daley, MD; M. Leigh Anne Daniels, MD, MPH; Edward Eden, MD; Angela DiMango, MD; Kevin Fennelly, MD; David E. Griffith, MD; Margaret M. Johnson, MD; Michael R. Knowles, MD; Mark L. Metersky, MD; Peadar G. Noone, MD; Anne E. O'Donnell, MD; Kenneth N. Olivier, MD, MPH; Matthias A. Salathe, MD; Andreas Schmid, MD; Byron Thomashow, MD; Gregory Tino, MD; and Kevin L. Winthrop, MD, MPH

e-Table 1. Results of the missing data analyses comparing characteristics of the participants included in and excluded from the multivariable multinomial regression analyses

	Included in the multinomial regression analyses, n=456	Excluded from the multinomial regression analyses* n=449	p-value
Age, mean (SD)	63 (14)	63 (15)	0.833
Female, n (%)	352 (77)	354 (79)	0.467
Caucasian, n (%)	417 (92)	406 (91)	0.706
NTM**, n (%)	119 (28)	135 (36)	0.027
Pre-bronchodilator FEV1 (L) at baseline, mean (SD)	1.80 (0.72)	1.85 (0.72)	0.266
Pre-bronchodilator FVC (L) at baseline, mean (SD)	2.67 (0.92)	2.72 (0.87)	0.446

SD=standard deviation; NTM=non-tuberculous mycobacteria; FEV_1=forced expiratory volume in one second; L=liter; FVC-=forced vital capacity; *Incomplete/missing data on frequency of exacerbations at baseline or follow-up year or *Pseudomonas aeruginosa;* **defined as history of NTM lung disease prior to enrollment, or ≥2 AFB positive sputum cultures, or ≥1 AFB bronchoalveolar lavage or transbronchial biopsy cultures.